Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 2/20 | 0.37 |
| ▸ | ATF1 | P18846 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23099869 | 0.83 | CCR1 (0.34) | GLP1RATF1NFKB1NOTUMKDM5B | |
| SCHEMBL2146161 | 0.80 | ATF1 (0.37) | PLAUGLP1RATF1NFKB1NOTUM | |
| SCHEMBL31539741 | 0.80 | GLP1R (0.38) | PLAUGLP1RATF1NFKB1DAO | |
| SCHEMBL24843396 | 0.80 | KDM4E (0.33) | GLP1RATF1NFKB1CYP1A2POLB | |
| SCHEMBL31409995 | 0.78 | PLAU (0.44) | PLAUDAOPOLB | |
| SCHEMBL18189517 | 0.75 | NOTUM (0.35) | GLP1RATF1NFKB1NOTUMALDH1A1 | |
| SCHEMBL31539768 | 0.73 | GRIN2D (0.37) | GLP1RATF1NFKB1DAOMEN1 | |
| SCHEMBL12874582 | 0.71 | PLAU (0.46) | PLAUDAONOTUMMEN1CYP1A2 | |
| SCHEMBL25584917 | 0.71 | GLP1R (0.37) | PLAUGLP1RATF1NFKB1MEN1 | |
| SCHEMBL16972785 | 0.70 | PLAU (0.48) | PLAUDAOMEN1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-31 | — | — | US | disclosed |
| EP-3288935-B1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | GRIN3A, GRIN1, GRIN2B | PLAU 4709/4885GLP1R 661/4885ATF1 2858/4885 |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | PLAU 4709/4885GLP1R 661/4885ATF1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.